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Objectives. Acute limb ischaemia is a common and often lethal clinical event. Reperfusion of an ischaemic limb has been
shown to induce a remote gut injury associated with transmigration of endotoxin into the portal and systemic circulation,
which in turn has been implicated in the conversion of the sterile inflammatory response to a sepsis syndrome, after lower
torso ischaemia-reperfusion injury. This study tests the hypothesis that an anti-endotoxin hyperimmune globulin attenu-
ates ischaemia-reperfusion (I/R) associated sepsis syndrome.
Design. Prospective, randomised placebo controlled trial, animal experiment.
Materials and methods. Experimental porcine model, bilateral hind limb I/R injury, randomised to receive anti-
endotoxin hyperimmune globulin or placebo.
Results. Bilateral hind limb I/R injury significantly increased intestinal mucosal acidosis, portal endotoxaemia, plasma
cytokine (TNF-alpha, IL-6, IL-8) concentrations, circulating phagocytic cell priming and pulmonary leukosequestration,
oedema, and capillary-alveolar protein leak. Conversely, pigs treated with anti-endotoxin hyperimmune globulin (IgG)
20 mg/kg at onset of reperfusion had significantly reduced portal endotoxaemia, early circulating phagocytic cell priming,
plasma cytokinaemia and attenuation of acute lung injury.
Conclusions. Endotoxin translocation across a hyperpermeable gut barrier, phagocytic cell priming and cytokinaemia are
key events of limb I/R injury induced systemic inflammation and acute lung injury. This study shows that an anti-
endotoxin hyperimmune globulin attenuates portal endotoxaemia, which may reduce early phagocytic cell activation,
cytokinaemia and ultimately acute lung injury.
Keywords: Ischaemia-reperfusion injury; Anti-endotoxin antibody; Systemic inflammatory response syndrome; Endotoxin;
Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS).Introduction
Acute limb ischaemia is a common and often lethal
clinical event.1 A national audit conducted by the Vas-
cular Surgical Society of Great Britain and Ireland into
outcomes in acute limb ischaemia reported an ampu-
tation rate of 16 percent and a mortality rate of 22 per-
cent respectively.2 Mortality rates in these patients
remain high after open or endovascular revascularisa-
tion due not only to co-existing cardiovascular disease
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reperfusion of the ischaemic limb.3,4 Reperfusion of
the ischaemic lower limb initiates the systemic inflam-
matory response syndrome (SIRS), characterised by
pro-inflammatory cytokine production, and increased
circulating polymorphonuclear (PMN) leucocyte
activation.5e7 After lower limb ischaemia-reperfusion
injury (IRI) pulmonary sequestration of activated
neutrophils is followed by acute pulmonary microvas-
cular injury, acute lung injury (ALI)whichmayprogress
to acute respiratory distress syndrome (ARDS), with
a subsequent high mortality.8e10
We and others have previously shown that lower
limb ischaemia reperfusion injury is associatedwith in-
creased intestinal permeability and endotoxaemia in
associationwith systemic inflammation andvital organ
dysfunction in models of limb ischaemia-reperfusionrved.
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and thoracic aortic aneurysm repair.13,14 It has been
postulated that the intestine is a source of inflammatory
propagation incritical illness. Endotoxin, a lipopolysac-
charide (LPS) component of the gram-negative bacte-
rial cell wall, has been shown to translocate from the
intestinal lumen to the portal circulation, thereby
providing a potent stimulus to cytokine production
and leukocyte activation.15,16 The precise role of endo-
toxin in systemic inflammation and sepsis syndrome
after vascular surgery remains controversial.17,20,21
This study tests the hypothesis that an anti-endotoxin
hyperimmune globulin may attenuate systemic inflam-
mation and acute lung injury after lower limb
ischaemia-reperfusion injury.
Methods
Experimental Protocol. The studies described herein
were performed in accordance with the Animals
(Scientific Procedures) Act 1986, and with approval
of our institution’s Animals Research Committee.
Experimental Model. In these series of experiments
we used an established large animal model of lower
limb ischaemia-reperfusion injury, as previously de-
scribed by Harkin, et al.7,18 In brief, male white Land-
race pigs (28e35 kg; 6e8 weeks old) were sedated
with stresnal (Azaperone BP; i.m. 2e3 mg/kg) prior
to induction and maintenance of anaesthesia with
Sagatal (sodium pentobarbital; i.v. 20 mg/kg and
8 mg/kg/h respectively), titrated to maintain apnoea.
A tracheostomy was created by insertion of a No. 7.5
endo-tracheal tube and mechanical ventilation (tidal
volume; 15 ml/kg) was instituted to maintain the
arterial partial pressure of CO2 (PaCO2) at 30e
42 mmHg. Hydration was maintained throughout
the experiment by infusion of compound sodium
lactate (Hartmann’s solution; Baxter Healthcare Ltd.,
UK; 15 ml/kg/h) and body temperature was main-
tained at 38.2 0.8 C. The left carotid artery was
catheterized (PE-190, Thomas, Philadelphia, PA,
USA) for continuous arterial blood pressure monitor-
ing, arterial blood gas sampling, and systemic blood
sampling. A balloon-tip pulmonary artery catheter
was guided into the pulmonary artery by pressure
wave-form analysis, for central venous (CVP), pulmo-
nary artery (MPAP), and intermittent pulmonary
arterial wedge (PAWP) pressure monitoring. Mean
pressures were determined using calibrated physio-
logical pressure transducers (Model 1280C) driving
an amplifier monitor (Model 7835A; Hewlett-Packard,
Andover, MA, USA). The left cephalic vein was catheter-
ized (PE-160; Thomas, Philadelphia, PA, USA) for con-
tinuous intravenous infusions of sodium pentobarbital(0.06 mg/kg/min) and Compound Sodium Lactate
solution (Hartmann’s solution, Baxter, UK). A 14-FG
silicon urinary catheter was placed in the bladder
for urine sampling. A 7-Fr catheter was advanced
through the splenic vein to the portal vein for blood
sampling. Tonometer’s (Tonometrics Inc., Bethesda,
Md, USA) were placed in the gastric antrum and
sigmoid colon endo-luminally, and terminal ileum
via enterotomy. After assuring haemostasis, the lapa-
rotomy was closed. Operative procedures took
approximately 60 min, after which subjects were stabi-
lised for 30 min, defined by constant heart rate, arterial
pressure, end-tidal CO2.
Experimental Design. Basal physiological values
were recorded after the 30-min recovery period. Blood
samples were taken from catheters placed in the sys-
temic, portal, hepatic, inferior vena cava sites. Animals
were randomised into three groups (n¼ 6 per group).
Two groups underwent bilateral external iliac artery
occlusion by application of bulldog arterial clamps
for 120 min followed by 150 min of reperfusion on
release of bulldog clamps. Absence of flow, and resto-
ration when appropriate, was confirmed using an
ultra-sonic flow probe (Transonic Systems Inc, USA)
applied to the vessel wall. Six pigs were allocated as
sham controls and kept for 270 min with recordings
as for the experimental animals (see below).
Treatment. Animals undergoing bilateral hind limb
ischaemia were randomised to receive treatment with
either Anti-endotoxin hyperimmune globulin (Anti-
LPS IgG) at 20 mg/kg body weight, or placebo vehicle
administered (n¼ 6 per group) by intravenous in-
fusion over 30 min from the beginning of reperfusion.
The endotoxin-core hyperimmune IgG immunoglobu-
lin was prepared from pooled plasma from human do-
nors with high tires of cross-reactive IgG antibodies to
endotoxin-core (EndoCAb), using a cold-ethanol pro-
cess followed by treatment at pH 4 in the presence of
pepsin and fresh dried for reconstitution, (a kind gift
from Dr G. Robin Barclay, PhD, formerly Edinburgh &
SE Scotland Regional Transfusion Centre, Scottish Na-
tional Blood Transfusion Service, R&D Laboratories, Edin-
burgh EH1 1EY, Scotland ).
Blood gas measurements. Arterial blood samples were
analysed in an automatic blood gas analyser (1304
pH/blood gas analyser, Instrumentation Laboratory,
Warrington, UK) without delay. Fraction inspired Oxy-
gen (FiO2). This was measured in a ventilatory circuit
using an Ohmeda 4700 Oxycap Monitor (Ohmeda,
1315 West Century Drive, Louisville CO 80027, USA).
Arterial-alveolar (A-a) gradient. This was measured
using the formula [(A-a) gradient¼ fraction inspired
O2 710(arterial pCO2/0.8)arterial pO2]. It is
a measure of lung function with a large gradientEur J Vasc Endovasc Surg Vol 33, March 2007
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lung injury, as previously described.18
Tonometry. Using balloon tonometry gut mucosal
pH was calculated by substituting the tonometry
derived PCO2 and the simultaneously measured
arterial bicarbonate in the Henderson-Hasselbalch
equation: pHi¼ 6.1þ log10([HCO3]/(0.03 PCO2ss))
(where 6.1 accounts for HCO3
 pK value at 37 C),
[HCO3
] is the measured arterial blood bicarbonate
concentration (mM/l); PCO2(ss) is the steady-state
time adjusted PCO2 (mmHg) of tonometer saline
and 0.03 is the CO2 solubility coefficient in plasma
[mM/l/mmHg] at 37 C, as previously described.18
SMA/Aorta Blood Flow Ratio. During laparotomy
ultrasonic flow probes (Transonic Systems Inc, USA)
were applied atraumatically to the vessel wall at the
origin of the superior mesenteric artery (SMA) and
infra-renal abdominal aorta. Continuous monitoring
of blood flow in litres per minute was recorded
during the experimental period allowing a ratio to
be calculated of SMA to aortic blood flow.
Intestinal permeability. Intestinal permeabilitywas as-
sessed as previously described by measuring the uri-
nary excretion of lactulose and mannitol administered
via oro-gastric tube immediately after induction of gen-
eral anaesthesia.18 The concentration of lactulose and
mannitol weremeasured enzymatically by the reduced
nicotinamide adenine dinucleotide (phosphate)-linked
enzymatic assays, modified from techniques described
by Northrop et al., and Lunn et al., respectively, using
a Cobras Fara centrifugal analyser (Roche Diagnostics,
WelwynGardenCity,UK). The amount of lactulose and
mannitol excretedwas calculated as a percentage of the
administered dose and intestinal permeability was
expressed as the lactulose: mannitol ratio.
Blood and Tissue sampling. Blood samples and mea-
surements were obtained every 30 min during the
experimental period. Blood samples were collected in
heparinized (20 U/mlBlood) sterile pyrogen-free tubes
and immediately transferred on ice to be spun at 200 g
(at 4 C) for 10 min. Plasma was aliquoted into sterile
cryotubes (Nunc, Intermed, Roskidle, Denmark) and
stored at 70 C until time of assay. Immediately after
blood sampling, a mid-line thoracotomy was per-
formed and samples of right lung were excised from
predetermined sites. Separate samples were either
fixed in 4% formalin for histological analysis or im-
mediately snap-frozen in liquid nitrogen and stored
at 70 C until assayed.
Luminol-enhanced chemiluminescence assay. Chemilu-
minescence was assayed using a luminal-dependent
CL assay as previously described.7 Respiratory burst
was triggered by the addition of 100 ml of phorbol 12-
myristate 13-acetate (PMA) into assay tubes. ActivityEur J Vasc Endovasc Surg Vol 33, March 2007is reported as the integral of the CL events registered
during the initial 10 min of activation. The degree of re-
spiratory burst activity is dependent on prior priming
in-vivo, further by maximally priming some samples
with addition of TNF-alpha to the diluted whole blood
a ratio could be determined between whole blood
priming and whole bloodþ TNF-alpha, thus compar-
ing in-vivo priming with maximal priming (%max).
Endotoxin. Endotoxin concentrationwas determined
using a quantitative Limulus amoebocyte lysate (LAL)
chromogenic assay (Quadratech, Epsom, UK.), as pre-
viously described.18 The detection limits of the assay
were between 0.1e1000 pg/ml, inter-assay and intra-
assay coefficient of variation were less than 10 per cent.
Interleukin-6 Assay. Biologically active IL-6 was
measured using a bioassay based on the proliferation
of IL-6-dependent B9 hybridoma cells (a generous gift
of L. Aarden, Amsterdam), as previously described.11,18
The concentration of IL-6 was computed from the stan-
dard curve. The detection limits of the assay were
between 100e5000 pg/ml, and inter-assay and intra-
assay coefficients of variation were less than 10 per cent.
Tumour Necrosis Factor(TNF)-alpha Assay. TNF-alpha
is measured by MTT tetrazolium cytotoxicity assay, as
previously described.11,18 The concentration of TNF-
alpha in each sample was computed from a standard
curve. The detection limits of the assay were between
0.02e200 pg/ml, and interassay and intraassay coeffi-
cients of variation were less than 10 percent.
Interleukin (IL)-8 and -10 assays. Plasma levels of
IL-8 and IL-10 were analysed by sandwich ELISA
according to the instructions of the manufacturer
(Biosource International Inc., 820 Flynn Road, Cama-
rillo, CA 93012, USA), as previously described.7
The detection limits of the assay were between
0.1e1000 pg/ml, and inter-assay and intra-assay
coefficients of variation were less than 10 per cent.
Measurement of Lung Tissue Myeloperoxidase (MPO).
Lung tissue myeloperoxidase activity was measured
spectrophotometrically (Beckmann DU-2 spectropho-
tometer:Beckmann Instruments, Inc., Cedar Grove,
N.J.), using the O-dianisidine hydrochloride method
in the presence of 0.0005% hydrogen peroxide, as
previously described.11,18 One unit of MPO activity
is defined as the amount required to degrade 1 mmol
of peroxide per minute at 25 C.
Lung Tissue wet-to-dry (W/D) weight ratios. W/D
ratios of lung and skeletal muscle tissue samples
(200e400 mg) were calculated.Each specimenwasblot-
ted dry, weighed then placed in a vacuum freeze dryer
at 70 C for 48 h. Specimens were then re-weighed
and the wet-to-dry tissue weight ratio was calculated.
Broncho-alveolar lavage (BAL). BAL was performed
through the endotracheal tube using a silastic
333Anti-LPS Antibody Reduces Inflammation in Limb IRIpulmonary suction catheter at 240 min, into the right
lung. All BAL was performed by the same person and
catheter placement confirmed on cadaver studies.
BAL fluid was centrifuged at 400 g at 4 C for 10 min,
and the supernatant was stored at 20 C. The BAL
protein content was measured in the non-cellular frac-
tion by the bicinchoninic acid (BCA) method.
Statistical Analysis
Summary values are expressed as mean SEM or me-
dian (interquartile range). One-way repeatedmeasures
analysis of variance was used to compare sequential
measurements for parametric data. Dunnett’s test was
used to make further comparisons if analysis of vari-
ance revealed significant differences. The control
value for Dunnett’s test was designated as the last
measurement obtained at the end of the baseline period
(time 0). Student’s t test was used for independent
comparisons for parametric data. Kruskall-Wallis H
analysis of variance was used in conjunction with
Mann-WhitneyU test for non-parametric comparisons.
A two-tailed p of<0.05 was considered statistically sig-
nificant. Statistical calculations were performed using
SPSS (Version 14.0, Microsoft, Redmond, WA)
software.
Results
Physiological and haemodynamic variables
There was no significant change in the mean base line
measurements for heart rate (HR), central venouspressure (CVP), or pulmonary capillary wedge pres-
sure (PCWP) throughout the experimental period,
suggesting optimal resuscitation. Mean arterial blood
pressure (MAP), was significantly increased in both
the I/R group and anti-LPS IgG treated I/R group,
compared to control, P< 0.01, during the ischaemic
period (t¼ 0e120) due to bilateral iliac artery clamp-
ing, but returned to baseline levels on clamp release
during the reperfusion period, (data not shown).
Effects of Limb Ischaemia-reperfusion on the Gut
Gut tonometry measurement
Temporal changes in gastric mucosal pH (pHigastric),
ileal mucosal pH (pHiileal), sigmoid mucosal pH
(pHisigmoid), variables at baseline and for each time
point during the experiment are shown in Table 1. A
significant fall is seen in gastric pHi (t¼ 210e270),
P< 0.05, and more notably sigmoid pHi during the
reperfusion period (t¼ 120e270), P< 0.01, in the
untreated I/R group compared to both control, and
this was not prevented by treatment with anti-LPS
IgG treated I/R group.
SMA/aorta blood flow ratio
A relative reduction in blood flow to the gut via the
SMA was seen in the I/R group during reperfusion
(t¼ 120e270), although this was not significant
and was unaltered by treatment with anti-LPS IgG,
Table 1.Table 1. The temporal changes in gastric mucosal pH, ileal mucosal pH, sigmoid mucosal pH, and fractional superior mesenteric artery
blood flow in the experimental groups
Baseline T¼ 60 T¼ 120 T¼ 150 T¼ 180 T¼ 210 T¼ 240 T¼ 270
Gastric-pHi
Control 7.38 0.06 7.25 0.03 7.23 0.04 7.23 0.03 7.21 0.04 7.25 0.03 7.17 0.05 7.16 0.05
I/R 7.25 0.09 7.22 0.11 7.22 0.11 7.15 0.10 7.16 0.10 7.14 0.09 7.07 0.08A 7.08 0.09
I/Rþ anti-LPS IgG 7.35 0.04 7.21 0.04 7.20 0.01 7.16 0.02 7.13 0.02 7.08 0.03A 7.06 0.04A 7.03 0.04A
Ileal-pHi
Control 7.26 0.04 7.28 0.02 7.23 0.04 7.29 0.01 7.29 0.01 7.23 0.02 7.22 0.03 7.27 0.04
I/R 7.34 0.05 7.26 0.05 7.26 0.02 7.23 0.02 7.24 0.02 7.21 0.02 7.13 0.07 7.21 0.07
I/Rþ anti-LPS IgG 7.46 0.05 7.37 0.04 7.38 0.03 7.28 0.03 7.23 0.02 7.21 0.02 7.21 0.05 7.22 0.04
Sigmoid-pHi
Control 7.26 0.04 7.19 0.04 7.18 0.05 7.16 0.02 7.15 0.03 7.17 0.04 7.12 0.04 7.15 0.05
I/R 7.21 0.07 7.10 0.07 7.14 0.04 7.08 0.03 7.11 0.04 7.06 0.05B 7.03 0.06B 7.02 0.07B
I/Rþ anti-LPS IgG 7.20 0.06 7.12 0.04 7.13 0.05 7.08 0.05B 7.06 0.06B 7.04 0.06B 7.02 0.07B 7.05 0.07
SMA/Aorta Blood
Flow Ratio (%)
Control 0.21 0.04 0.27 0.04 0.27 0.05 0.32 0.09 0.32 0.09 0.34 0.09 0.32 0.07 0.32 0.07
I/R 0.17 0.02 0.26 0.03 0.26 0.03 0.20 0.03 0.22 0.04 0.23 0.05 0.26 0.05 0.26 0.06
I/Rþ anti-LPS IgG 0.19 0.04 0.26 0.06 0.25 0.04 0.21 0.04 0.22 0.03 0.22 0.03 0.22 0.03 0.21 0.03
A P< 0.05 vs. control group.
B P< 0.01 vs. control group.Eur J Vasc Endovasc Surg Vol 33, March 2007
334 D. W. Harkin et al.Lactulose/mannitol urinary excretion ratio
The lactulose/mannitol (L/M) urinary excretion ratio
was significantly greater in the I/R group, 0.19 0.03,
compared to control group, 0.09 0.03, p< 0.02, this
was not altered by treatment with anti-LPS IgG.
Endotoxaemia
Portal vein endotoxin concentration increased during the
reperfusion period in I/R group, 505.70 (413.70e
530.70) pg/ml, compared to control group, 18.92
(10.27e59.75), p< 0.009, and significantly attenuated
in the anti-LPS IgG treated I/R group, 8.49 (7.48e
31.25), p< 0.05. (Fig. 1A). There was a significant,
p< 0.008, positive correlation, r¼ 0.604, between
plasma portal endotoxin concentration and L/M
urinary excretion ratio, Spearman’s rank correlation.
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Fig. 1. A: Portal endotoxin (pg/ml) in control, I/R, and anti-
LPS IgGþ I/R groups. AP< 0.009 compared with control.
BP< 0.05 compared with I/R group. B: Systemic endotoxin
(pg/ml) in control, I/R, and anti-LPS IgGþ I/R groups.
Data represents mean SEM.Eur J Vasc Endovasc Surg Vol 33, March 2007Systemic vein endotoxin concentrations were com-
parible in the I/R and control groups in the reperfu-
sion period. In the I/R group the endotoxin
concentration in the systemic circulation fell during
reperfusion timepoints t¼ 180, 11.30 (0.00e61.00),
and t¼ 270, 16.20 (0.00e49.60), compared to the portal
vein at t¼ 180, 500 (472e514.20), p< 0.01, and t¼ 270,
505.70 (413.70e530.70), p< 0.001, respectively,
(Fig. 1B).
Cytokine Response
Plasma tumour necrosis factor(TNF)-alpha
Portal vein TNF-alpha concentration was significantly
elevated after one hour of reperfusion (t¼ 180) in
the I/R group, 229.69 (194.35e274.74) pg/ml, com-
pared to control group, 3.93 (0.0e41.35) pg/ml, and
anti-LPS IgG treated I/R group, 20.15 (14.66e27.79),
p< 0.001. This effect persisted through reperfusion.
(Fig. 2A).
Systemic vein TNF-alpha concentrationwas also signif-
icantly greater after one hour of reperfusion (t¼ 180) in
the I/R group, 86.83 (40.79e158.99) pg/ml, compared
to control group, 32.67 (0.95e42.82) pg/ml, and anti-
LPS IgG treated I/R group, 10.84 (5.78e12.3), p< 0.05.
In the I/R group significantly less TNF-alpha was
detected during reperfusion in the systemic circulation
as compared to the portal circulation, p< 0.01. (Fig. 2B)
Plasma Interleukin (IL)-6
Portal vein IL-6 concentration was significantly greater
after one hour of reperfusion (t¼ 180) in the I/R
group, 1869.0 (1697.0e2090.4) pg/ml, compared to
control group, 364.1 (290.3e413.0) pg/ml, p< 0.001,
and anti-LPS IgG treated I/R group, 1207.0 (1138.3e
1428.4), p< 0.01. This effect persisted through reperfu-
sion. (Fig. 3A).
Systemic vein IL-6 concentration was significantly
greater after one hour of reperfusion (t¼ 180) in
the I/R group, 1726.0(1130.0e2130.0) pg/ml, com-
pared to control group, 303.5(274.4e374.3 pg/ml,
p< 0.003), and this was not attenuated in the
anti-LPS IgG treated I/R group. (Fig. 3B).
Plasma interleukin (IL)-8
Systemic vein IL-8 concentration was significantly ele-
vated after 1 h of reperfusion (t¼ 180) in the I/R
group, 198.1 (116.1e373.9), compared to control
group, 49.5 (37.8e73.7), p< 0.03, and the anti-LPS
IgG treated I/R group, 74.7 (57.6e104.75) pg/ml,
335Anti-LPS Antibody Reduces Inflammation in Limb IRIp< 0.008. This effect was maintained throughout
reperfusion.
Plasma IL-10
Systemic IL-10 concentration was not significantly
altered from baseline throughout the experimental
period in control, or I/R groups.
Phagocytic Cell Priming for
Respiratory Burst Activity
Phagocytic cell priming ratio from whole-blood
chemiluminescence assay
Portal vein phagocytic cell priming ratio was significantly
greater during early reperfusion (t¼ 150) in the I/R
group, 0.76 0.05, compared to control group,
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Fig. 2. A: Portal TNF-alpha (pg/L) in control, I/R, and anti-
LPS IgGþ I/R groups. AP< 0.001 compared with control
and anti-LPS IgGþ I/R. BP< 0.001 compared with I/R
group. B: Systemic TNF-alpha (pg/L) in control, I/R, and
anti-LPS IgGþ I/R groups. AP< 0.05 compared with
control and anti-LPS IgGþ I/R groups. Data represents
mean SEM.0.54 0.06, p< 0.01, and compared to anti-LPS IgG
treated I/R group, 0.62 0.05, p< 0.05.After twohours
of reperfusion (t¼ 240) the priming ratio remained
significantly greater in the I/R group, 0.81 0.11
compared to control group, 0.24 0.04, p< 0.001, and
anti-LPS IgG treated group, 0.55 0.08, p< 0.05. The
priming ratio decreased significantly in the control
group from the start (t¼ 0), 0.59 0.06, to the end
(t¼ 240), 0.24 0.04, p< 0.005. Priming increased in
the I/R group from t¼ 0 to t¼ 240, 0.56 0.20 com-
pared to 0.81 0.11, although this did not reach signif-
icance. (Fig. 4A).
Systemic vein phagocytic cell priming ratio was signif-
icantly greater during early reperfusion (t¼ 150) in
the I/R group, 1.01 0.08, compared to control group,
0.56 0.11, p< 0.01, and compared to anti-LPS IgG
treated I/R group, 0.80 0.03, p< 0.05. After two
hours reperfusion (t¼ 240) the priming ratio remain-
ed significantly greater in the I/R group, 0.86 0.12,
compared to control group, 0.26 0.07, p< 0.001,
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pared with I/R group. B: Systemic IL-6 (pg/L) in control,
I/R, and anti-LPS IgG groups. AP< 0.003 compared with
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336 D. W. Harkin et al.and this was not attenuated in the anti-LPS IgG
treated group, 0.83 0.14. (Fig. 4B).
Whole blood leucocyte counts
There was no difference in total whole blood leuco-
cyte count, nor was there any difference in the neutro-
phil fraction, between the control group and the I/R
group throughout the experimental perior.
Acute Lung Injury
Pulmonary physiology
Arterial partial pressure of oxygen (pO2 in mmHg)
fell significantly during the reperfusion period in the
I/R group compared to control group, P< 0.05, and
attenuated in the anti-LPS IgG treated I/R group,
P< 0.01. (Fig. 5A).
Pulmonary artery pressure (PAP) was significantly
greater during reperfusion in the I/R group compared
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control. BP< 0.05 compared with I/R group.Eur J Vasc Endovasc Surg Vol 33, March 2007to control group, p< 0.001, and significantly attenu-
ated in early reperfusion in the anti-LPS IgG treated
I/R group, p< 0.001. However, this protective effect
was lost in late reperfusion, (Fig. 5B).
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337Anti-LPS Antibody Reduces Inflammation in Limb IRIAlveolar-arterial (A-a) O2 gradient values were
similar during the ischaemia period but were signifi-
cantly higher A-a gradient after reperfusion in the
I/R group compared to control, p< 0.05, suggesting
impaired alveolar oxygen transport. This impairment
in oxygen transport was not prevented in the anti-
LPS IgG treated I/R group, (Fig. 5C).
Lung tissue myeloperoxidase
The lung tissue myeloperoxidase concentration was
significantly greater in the I/R group, 33.81 (15.65e
52.66) units of absorbance per gram dry tissue, com-
pared to control group, 7.54 (0.97e8.63), p< 0.005.
This was not attenuated in the anti-LPS IgG treated
group, 25.74 (15.89e38.63). (Fig. 6A)
BAL non-cellular fraction protein concentration
The BAL protein concentration was significantly
greater after 2 h of reperfusion (t¼ 240) in the I/R
group, 0.72 (0.31e1.60), compared to control group,
0.23 (0.18e0.31), p< 0.05. This increase was not atten-
uated in the anti-LPS IgG treated I/R group, 0.58
(0.44e0.74). (Fig. 6B)
Lung tissue wet-to-dry weight ratio
The lung wet-to-dry tissue weight ratio was signifi-
cantly greater in the I/Rgroup, 10.13 (7.66e12.66), com-
pared to control group, 5.57 (4.54e7.37), p< 0.01. This
increase was not attenuated in the anti-LPS IgG treated
I/R group, 8.26 (7.06e11.09). (Fig. 6C)
Spearman’s rank correlation: correlation MPO and
W/D ratio, P< 0.0001, r¼ 0.57; correlation BAL pro-
tein and W/D ratio, P< 0.05, r¼ 0.389.
Discussion
In vascular surgery practise patients are commonly
exposed to lower limb ischaemia-reperfusion injury
during the management of acute limb ischaemia,
during revascularization surgery of the lower limb,
or during aortic aneurysm repair.2,3,8 The conversion
of lower limb skeletal muscle ischaemia-reperfusion
injury into a harmful systemic inflammatory response
has been demonstrated in both experimental models11
and clinical studies.12 In many patients reperfusion
injury may be mild and self-limiting, but reperfusion
after prolonged ischaemia of large vascular territories
is often lethal.6 We have shown that severe limb IRI
results in remote intestinal injury, and is associatedwith a significant increase in gastric, ileal, and sig-
moid mucosal acidosis.11,18 Furthermore, that intesti-
nal permeability was increased and associated
with a significant increase in portal endotoxin
concentration. Treatment with anti-LPS IgG, given
post-ischaemia at the start of the reperfusion period,
as expected had no effect on intestinal permeability
or intestinal mucosal acidosis, but was associated
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338 D. W. Harkin et al.with a significant reduction in portal endotoxaemia. It
is most likely this reduction in portal endotoxin con-
centration is due to increased leucocyte mediated
clearance of endotoxin rather than a reduction in
transmigration. Endotoxin, a lipopolysaccharide
(LPS) component of the wall of gram-negative bacte-
ria, is undoubtedly a potent stimulus to cytokine
production and activation of PMN.15,22 Impaired
splanchnic blood flow has been suggested as a cause
of extended gut injury in sepsis.23 In this model
SMA blood flow was reduced as a fraction of total aor-
tic blood flow during reperfusion, although this did
not reach significance. Sepsis syndrome remains
a leading cause of mortality, and although several
classes of LPS-binding compounds have shown prom-
ise in basic studies,24 early clinical trials using anti-
LPS monoclonal antibodies have produced equivocal
results.24,25 In this study we have used an anti-
endotoxin hyperimmune globulin which has been
shown to increase endotoxin binding and clearance
by leucocytes,22,25 due to it’s polyclonal nature it is
considered much more likely to neutralize LPS de-
rived from the heterogenous bacterial flora of the
gut. In this study we have shown increased portal
and circulating whole blood phagocytic cell priming
after lower limb IRI. Treatment with anti-LPS IgG re-
duced portal endotoxaemia and early phagocytic cell
priming. Priming of PMN to produce reactive oxidant
species, by prior exposure to inflammatory stimulus,
is thought to be central to the role of PMN-mediated
anti-microbial activity and tissue damage in response
to a secondary stimulus,7,19 and is known to be upre-
gulated by exposure to endotoxin.26 Furthermore,
treatment with Anti-LPS IgG and reduction in portal
endotoxaemia in this model was associated with sig-
nificant reduction in pro-inflammatory cytokine con-
centrations (TNF-alpha and IL-6) in the portal vein.
Although it is not possible from these data to confirm
the source of these cytokines, greater concentrations
in the portal circulation during reperfusion suggest
a splanchnic origin. Animal studies of intestinal is-
chaemia-reperfusion injury,15,27 and human patients
undergoing aneurysm surgery,28 have shown the
portal circulation to be the main source of early pro-
inflammatory cytokine production. We did not show
significant evidence of systemic endotoxaemia in
this study. The hepatic macrophages (Kupffer cells)
clear endotoxin and bacteria from the portal circula-
tion during health and disease,29 although in severe
sepsis this system can be overwhelmed or even con-
tribute to systemic inflammation through hepatic cy-
tokine production. Pro-inflammatory cytokines such
as TNF-alpha and IL-6 have been shown to be associ-
ated with neutrophil priming and delayed apoptosis,Eur J Vasc Endovasc Surg Vol 33, March 2007and as such may increase the functional activity and
longevity of PMN.30,31 IL-8, a powerful chemoattrac-
tant cytokine,32 was also elevated in this model, and
abrogated by treatment with anti-LPS IgG. The bal-
ance between pro- and anti-inflammatory stimuli is
crucial to the propagation or resolution of inflamma-
tion, and beneficial effects of LPS-therapy in these
studies may render recoverable a potentially lethal in-
flammatory syndrome.
In this study the development of remote pulmonary
dysfunction was observed only following reperfusion,
with development of hypoxaemia, pulmonary
hypertension, and impaired oxygen transport. The
prevention of this acute pulmonary dysfunction in
the anti-LPS IgG treated group suggests a role for endo-
toxin induced circulating neutrophil activation in the
development of this lung injury. Early signs of adult re-
spiratory distress syndrome (ARDS), which carries
a high mortality, have been reported within hours of
aortic declamping in human abdominal aortic aneu-
rysm repair and animal models of reperfusion injury.10
The importance of neutrophils in post-reperfusion
tissue injury has been confirmed by the attenuation of
local limb and remote lung injury in leukopenicmodels
of lower limb ischaemia-reperfusion injury.19,33
Elevated levels of lung tissue myeloperoxidase, BAL
protein concentration, andwet-to-dryweight ratio sug-
gesting a neutrophilmediated acute lung injury charac-
terised by increased microvascular permeability and
leukocytic sequestration within the lung. Although
there was a reduction in all these measures of injury
after treatmentwith anti-LPS IgG, thesewerenot signif-
icant. Despite a reduction in portal endotoxaemia and
inflammation in this model measures of lung tissue
injury were not attenuated by anti-LPS IgG which
may reflect the numerous parallel inflammatory path-
ways which are activated in reperfusion injury due to
vasoactive mediators.8,10,17,34
Conclusions
There is persistent evidence supporting a role for gut
hyper-permeability and translocation of endotoxin in
the propagation of the inflammatory response to sig-
nificant lower torso ischaemia-reperfusion injury. If
gut-endotoxin converts a recoverable inflammatory
response to a lethal endotxaemia in a certain subset
of patients then anti-endotoxin strategies may still
have an important role in the treatment of these
patients. In conclusion we have shown that anti-LPS
IgG can reduce portal endotoxaemia, cytokinaemia
(TNF-alpha, IL-6), neutrophil priming, and remote
acute pulmonary dysfunction seen after hind limb
ischaemia-reperfusion injury.
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